Document is current
Any future updates will be listed below
-
Authors
Janssens, Rosanne https://orcid.org/0000-0003-1982-4176
Huys, Isabelle
van Overbeeke, Eline
Whichello, Chiara
Harding, Sarah
Kübler, Jürgen
Juhaeri, Juhaeri
Ciaglia, Antonio
Simoens, Steven
Stevens, Hilde
Smith, Meredith
Levitan, Bennett
Cleemput, Irina
de Bekker-Grob, Esther
Veldwijk, Jorien
-
Funding
Funding for this research was provided by:
The EU/EFPIA Innovative Medicines Initiative [2] Joint Undertaking PREFER (115966)
- License Information
-
More Information
Article History
Received: 27 August 2018
Accepted: 23 July 2019
First Online: 4 October 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: Dr. Veldwijk, Dr. de Bekker-Grob, Dr. Simoens, Dr. Stevens, Dr. Ciaglia have nothing to disclose. Ms. Janssens, Dr. Huys, Ms. van Overbeeke, Ms. Whichello and Dr. Cleemput report grants from the EU/EFPIA Innovative Medicines Initiative [] Joint Undertaking, during the conduct of the study. Dr. Juhaeri is an employee of Sanofi, a bio-pharmaceutical company. He owns Sanofi stock option and restricted shares and he has investments that may include stocks of other bio-pharmaceutical companies at certain points in time. Dr. Harding reports other from Takeda International - UK Branch, outside the submitted work. Dr. Küblers’ work was funded by CSL Behring. Dr. Smith is an employee of Amgen, Inc. and owns stock in Amgen, AbbVie, and Abbott. Dr. Levitan is an employee of Janssen Research and Development, LLC. Dr. Levitan is a stockholder in Johnson & Johnson, Baxter International, Inc., Pharmaceutical Holders Trust, and Zimmer Holdings, Inc. Dr. Levitan also owns stock in a variety of companies that at times include other pharmaceutical and health care-related companies.
